CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies

Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived chimeric antigen receptor (CAR) natural killer (NK) cell therapy targeting CD19.

Leave a Comment

Your email address will not be published. Required fields are marked *

Shopping Cart
This website uses cookies and asks your personal data to enhance your browsing experience.